IAPO's participation at the 156th session of the WHO Executive Board

The 156th session of the World Health Organization Executive Board (EB156) was held between 3-11 February where the 34-member Board examined pressing global health challenges and prepared key decisions for the upcoming World Health Assembly. IAPO's participation at EB156 included joining six constituency statements on critical issues: two on Universal Health Coverage (led by Rare Diseases International and the World Federation of Nuclear Medicine & Biology), two on Health emergencies (led by Global Health Council and International Federation of Pharmaceutical Manufacturers and Associations), one on Climate change and health (led by World Heart Federation) and one on Involvement of Non-State Actors in WHO's governing bodies (led by Global Health Council).

We also supported the World Heart Federation's statement on behalf of the Fight the Fakes Alliance, which IAPO is part of, addressing substandard and falsified medical products.  

Additionally, IAPO actively supported two draft resolutions recommended for adoption at the 78th World Health Assembly in May: one on rare diseases – through our engagement in the Coalition in Support of the Resolution on Rare Diseases led by Rare Diseases International – and one on skin diseases – through our engagement as a member of the World Skin Health Coalition. We have also supported another draft resolution on strengthening medical imaging capacity, which was equally recommended for adoption at the WHA78.  

Renewal of IAPO's official relations status as an NSA

IAPO is pleased to announce the renewal of our official relations status as a Non-State Actor (NSA) with the World Health Organization during the 156th WHO Executive Board Meeting. This renewal of our collaboration reaffirms our commitment to ensuring patient voices remain central in global health decision-making.